---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-016468"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:27:37.957958+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aprea reports Phase 1 safety data for ATRN-119; no hematologic or liver toxicities; WEE1i ATRN-1051 IND planned Q4 2023

## Summary
- ATRN-119 Phase 1/2a dose escalation shows no hematologic or liver toxicities across first three cohorts (50, 100, 200 mg) in heavily pretreated solid tumor patients.
- One stable disease observed at 50 mg low dose; dose expansion cohort on track for Q2 2024; currently enrolling 350 mg cohort.
- Pre-clinical data for WEE1i ATRN-1051 shows high selectivity for WEE1 and low off-target activity against PLK kinases; IND submission planned for Q4 2023.
- ATRN-1051 preclinical findings also show limited effects on red blood cell counts, hERG inhibition, and body weight loss compared to other WEE1 inhibitors.

## SEC filing metadata
- accession: 0001558370-23-016468
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000155837023016468/0001558370-23-016468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000155837023016468/apre-20231016x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-016468
- JSON: https://secwatch.observer/filing/0001558370-23-016468.json
- Plain text: https://secwatch.observer/filing/0001558370-23-016468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.